KPC Pharmaceuticals (SHSE:600422) Construction In Progress: ¥111 Mil (As of Mar. 2026)


SHSE:600422 KPC Pharmaceuticals Inc SHSE:600422
62 GF Score
Price ¥8.27
GF Value ¥11.83
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is KPC Pharmaceuticals Construction In Progress?

KPC Pharmaceuticals SHSE:600422 -0.36% 62 Construction In Progress is ¥111 Mil as of Mar. 2026. GuruFocus rates SHSE:600422 with a GF Score™ of 62/100 and a GF Value™ of ¥11.83 (Significantly Undervalued). The stock has 7 warning signs investors should review.

KPC Pharmaceuticals's quarterly construction in progress increased from Sep. 2025 (¥78 Mil) to Dec. 2025 (¥100 Mil) and increased from Dec. 2025 (¥100 Mil) to Mar. 2026 (¥111 Mil).

KPC Pharmaceuticals's annual construction in progress declined from Dec. 2023 (¥101 Mil) to Dec. 2024 (¥76 Mil) but then increased from Dec. 2024 (¥76 Mil) to Dec. 2025 (¥100 Mil).

KPC Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for KPC Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KPC Pharmaceuticals Construction In Progress Chart

KPC Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.51 64.65 100.51 76.46 100.40

KPC Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.86 86.18 77.81 100.40 110.62
SHSE:600422
62GF Score
KPC Pharmaceuticals Inc SHSE:600422
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

KPC Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥111 Mil mean?
KPC Pharmaceuticals (SHSE:600422) has a Construction In Progress of ¥111 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on KPC Pharmaceuticals and its competitors.
Is KPC Pharmaceuticals' Construction In Progress too high?
KPC Pharmaceuticals' current Construction In Progress is ¥111 Mil. Overall, KPC Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KPC Pharmaceuticals' Construction In Progress compare to ZTS and UTHR?
KPC Pharmaceuticals' Construction In Progress of ¥111 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on KPC Pharmaceuticals and its competitors. KPC Pharmaceuticals's current Construction In Progress is ¥111 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KPC Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥11.83, compared to a current price of ¥8.27 — trading 30.1% below its estimated fair value. The current Construction In Progress is ¥111 Mil. KPC Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current Construction In Progress is ¥111 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?

Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued. The current stock price of ¥8.27 is trading 30.1% below its estimated GF Value™ of ¥11.83. GuruFocus considers KPC Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for SHSE:600422:

  • Construction In Progress: ¥111 Mil
  • GF Value™: ¥11.83 vs. price of ¥8.27 (30.1% below fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

KPC Pharmaceuticals Business Description

Address No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
62GF Score

Get the complete analysis for SHSE:600422

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.27
Price
¥11.83
GF Value